Voss Capital LP Boosts Stake in Actuate Therapeutics, Inc. $ACTU

Voss Capital LP raised its holdings in shares of Actuate Therapeutics, Inc. (NASDAQ:ACTU) by 213.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 896,278 shares of the company’s stock after buying an additional 610,138 shares during the period. Voss Capital LP owned about 3.86% of Actuate Therapeutics worth $5,996,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. BIOS Capital Management LP raised its holdings in shares of Actuate Therapeutics by 0.7% in the second quarter. BIOS Capital Management LP now owns 9,965,079 shares of the company’s stock worth $60,887,000 after buying an additional 71,428 shares during the period. Bank of America Corp DE boosted its holdings in Actuate Therapeutics by 61,068.0% during the 2nd quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock valued at $93,000 after acquiring an additional 15,267 shares during the period. New York State Common Retirement Fund bought a new position in Actuate Therapeutics in the 2nd quarter valued at $105,000. Northwestern Mutual Wealth Management Co. grew its position in Actuate Therapeutics by 492.6% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 18,518 shares of the company’s stock valued at $113,000 after acquiring an additional 15,393 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Actuate Therapeutics by 98.7% in the first quarter. Goldman Sachs Group Inc. now owns 22,358 shares of the company’s stock worth $151,000 after purchasing an additional 11,105 shares during the period.

Actuate Therapeutics Stock Up 3.4%

Shares of NASDAQ:ACTU opened at $2.77 on Wednesday. The business’s 50 day moving average is $4.40 and its 200 day moving average is $6.06. The stock has a market cap of $64.38 million, a P/E ratio of -3.18 and a beta of 0.12. Actuate Therapeutics, Inc. has a 52-week low of $2.33 and a 52-week high of $11.99.

Analyst Ratings Changes

Several research firms have recently weighed in on ACTU. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Actuate Therapeutics in a research report on Wednesday, November 19th. Wall Street Zen cut shares of Actuate Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Actuate Therapeutics in a research note on Monday, December 29th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.33.

Insider Buying and Selling at Actuate Therapeutics

In other Actuate Therapeutics news, Director Todd S. Thomson sold 280,000 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $5.80, for a total value of $1,624,000.00. Following the completion of the sale, the director directly owned 904,795 shares in the company, valued at approximately $5,247,811. This represents a 23.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 69.34% of the company’s stock.

Actuate Therapeutics Company Profile

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.